During the past decade, Thomas Jefferson University Hospital;Medical Oncology conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 4 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Thomas Jefferson University Hospital;Medical Oncology" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Pfizer" with 3 trials sponsored, "Celgene" with 2 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "Polynoma LLC" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Thomas Jefferson University Hospital;Medical Oncology" #1 collaborator was "Astellas Pharma Inc" with 2 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 2 trials as a collaborator and "Amalgam Rx" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Thomas Jefferson University Hospital;Medical Oncology" are "Melanoma" (2 trials), "Prostate Cancer" (2 trials), "Advanced BRAFV600 Wild-type Melanoma" (1 trials), "Cancer of the Prostate" (1 trials) and "Cutaneous Melanoma" (1 trials). Many other conditions were trialed in "Thomas Jefferson University Hospital;Medical Oncology" in a lesser frequency.

Most popular intervention types in "Thomas Jefferson University Hospital;Medical Oncology" are "Drug" (7 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "Enzalutamide" (2 trials), "Abemaciclib" (1 trials), "Adalimumab" (1 trials) and "Bendamustine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Thomas Jefferson University Hospital;Medical Oncology" are 7 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Thomas Jefferson University Hospital;Medical Oncology". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Thomas Jefferson University Hospital;Medical Oncology, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Thomas Jefferson University Hospital;Medical Oncology, 4 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".